

NASOVAC-S4

Quadrivalent Intranasal Influenza Vaccine

India's 1st Needle-free Influenza (Seasonal Flu) Vaccine

Developed & Manufactured by Serum Institute of India



Estimated 1 billion cases of influenza occur globally

Annual attack rate estimated at 5%–10% in adults and 20%–30% in children

Estimated to infect unvaccinated population 1 in 5 children & 1 in 10 adults

Source: <https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality/influenza>

Wave good bye to flu shots, say hello to a painless vaccine.



Benefits of NASOVAC-S4

Intranasal vaccination offers several advantages over traditional injectable vaccines, including:



Quadrivalent vaccine that offers broad immune response over trivalent vaccines



Needle-free vaccine which is non-invasive and painless



Intranasal vaccination mimics the natural route of infection



Double protection with mucosal and systemic immune response



Indications

Suitable for individuals aged **2 years and above**



Contraindications

Not suitable for individuals allergic to egg proteins (Consult your doctor to know more)



Quadrivalent vaccine that provides overall seroconversion of:

Type A

H1N1 - 93.7%
H3N2 - 81.2%

Type B

Victoria lineage - 88%
Yamagata lineage - 84.3%

NASOVAC-S4 Product Details

NASOVAC-S4 is a live attenuated quadrivalent vaccine that protects from four virus strains



2 Type A - H1N1 & H3N2



2 Type B - Victoria and Yamagata lineage



Dosage: A single intranasal dose of 0.5 ml, administered as 0.25 ml per nostril



Form: Liquid



Shelf Life: 9 months from the date of manufacture



Storage Requirements: Store in a refrigerator at 2°C - 8°C. Do not freeze




Scan for Administration
Method Video

Recommendations for Seasonal Flu Vaccination

World Health Organization (WHO)

- Recommends Annual Influenza (Seasonal Flu) Vaccination
- WHO recommends quadrivalent vaccines for use in the 2023-2024



Scan to visit

Source:
<https://www.who.int/news/item/24-02-2023-recommendations-announced-for-influenza-vaccine-composition-for-the-2023-2024-northern-hemisphere-influenza-season>

Indian Academy of Pediatrics (IAP)

- Recommends annual flu vaccination



Scan to visit

Source:
<https://acvip.org/professional/columns/influenza-vaccine>



Mylab Discovery Solutions Pvt. Ltd.

Global Innovation Center (GIC) 5th Floor, Amar Paradigm, Survey No - 110/11/3, Baner Road, Pune - 411045, Maharashtra, India.

Email: business@mylabglobal.com | Web: www.mylabglobal.com

 mylabsolutions  mylabsolutions  mylabdiscoverysolutions  mylabdiscoverysolutions